Michael Calabrese Comments on Wall Street’s Challenge to New SEC Private Fund Adviser Rule
September 1, 2023
The Hill
Foley & Lardner LLP partner Michael Calabrese is quoted in The Hill article, “Wall Street fights back against new SEC reforms in scathing lawsuit,” discussing a recent lawsuit filed by a cohort of trade associations challenging the SEC’s new Private Fund Adviser rule.
“The failure to include standard of care language in the final rule really leaves investors with no greater protection than if the new rules had not been adopted,” Calabrese explained. “In some ways, this runs counter to one of the principles that seemed to underlie the Commission’s efforts – discouraging preferential treatment.”
“Larger investors, and those with statutory or policy mandates on this issue, will continue to get better results here than others,” Calabrese added.
People
Related News
May 1, 2026
In the News
David Rosen Weighs in on SCOTUS Review of Skinny Label Patent Dispute
Foley & Lardner LLP partner David Rosen is featured across the media for his perspective on the U.S. Supreme Court case Hikma Pharmaceuticals v. Amarin Pharma.
April 27, 2026
In the News
Jesse Neil Featured as a Distinguished Leader in Law.com's Southeastern Legal Awards
Foley & Lardner LLP partner Jesse Neil is recognized in Law.com as one of the Distinguished Leader honorees for the 2026 Southeastern Legal Awards.
April 27, 2026
In the News
David Rosen and William Holtz Analyze FDA Approval Speed, Biotech Pressures
Foley & Lardner LLP attorneys David Rosen and William Holtz are quoted in the PharmaVoice article, “FDA’s need for speed could strain small biotechs. Here’s how they can keep up,” examining the FDA’s accelerated drug approval initiatives and its impact on smaller pharmaceutical companies.